Cingulate Shares Drop After FDA Issues Complete Response Letter for ADHD Drug
Cingulate Inc. (NASDAQ: CING) saw its stock fall roughly 20% following disclosure that the U.S. Food and Drug Administration issued a Complete Response Letter for the company's New Drug Application for CTx-1301, an attention deficit/hyperactivity disorder treatment. The FDA's response focused on Chemistry, Manufacturing and Controls (CMC) informati…